Bristol-Myers Squibb to Expand Oncology Portfolio with $4.8 Billion Mirati Acquisition
- October 13, 2023
Pharmaceutical giant Bristol Myers Squibb (BMS) plans to buy Mirati Therapeutics, Inc., which focuses on developing breakthrough cancer therapies, in a transaction valued of $4.8 billion, the companies announced October 10.
ARTICLE TAGS
You must be logged in to access this content.